Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2019

01-04-2019 | Review

Mexican rheumatology: where do we stand?

Authors: Carlos Pineda, Hugo Sandoval, Antonio Fraga-Mouret

Published in: Rheumatology International | Issue 4/2019

Login to get access

Abstract

The aim of this review was to provide an overall overview of the past, present, and future situations and main challenges that are facing Mexican Rheumatology as a medical subspecialty in the context of their national healthcare system, where a deficit of workforce at the national level coexists with a shortage of specialists in the less-developed southern states of the country and a great surplus of professionals within large metropolitan areas. We also analyzed the prevalence and burden of Rheumatic and Musculoskeletal Diseases (RMDs), the structural composition and distribution of Mexican Rheumatology, and the clinical profile of the Mexican Rheumatologist. Last, we examined comorbidities, education and training programs and one scenario for Mexican Rheumatology wherein the principal main threats and opportunities are determined.
Literature
1.
2.
3.
Cardiel MH (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology 45(Suppl 2):ii7–ii22PubMed
4.
Pineda C, Sandoval H (2017) Defining quality of rheumatologic care: Mexico. J Clin Rheumatol 23(4):209–211CrossRefPubMed
5.
OECD (2016) OECD reviews of health systems: Mexico 2016. OECD Publishing, ParisCrossRef
6.
Cardiel MH, Díaz-Borjoón A, Vázquez del Mercado Espinosa M et al (2014) Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis. Reumatol Clin 10(4):227–240CrossRefPubMed
7.
Badia Flores JJ, Arévalo Martínez FG (2009) Reumatólogos mexicanos. Distribución nacional del año 2007 y proyección al 2025. Reumatol Clin 5(3):140–141CrossRefPubMed
8.
Loyola-Sánchez A, Richardson J, Peláez-Ballestas I et al (2017) Physical function assessment of a Mayan population living with osteoarthritis: the importance of considering different aspects of functioning. Rehabil Process Outcome 6:1–9CrossRef
9.
Álvarez-Nemégyei J, Peláez-Ballestas I, Goñi M et al (2016) Prevalence of rheumatic regional pain syndromes in Latin-American indigenous groups: a census study based on COPCORD methodology and syndrome-specific diagnostic criteria. Clin Rheumatol 35:63–70CrossRefPubMedPubMedCentral
10.
Del Río Nájera D, González-Chávez SA, Quinoñez-Flores CM, Peláez-Ballestas I, Hernández-Nájera N, Pacheco-Tena CF (2016) Rheumatic diseases in Chihuahua, Mexico: a COPCORD Survey. J Clin Rheumatol 22(4):188–193CrossRefPubMed
11.
Hernández-Cáceres AE, Rodríguez-Amado J, Peláez-Ballestas I, Vega-Morales D, Garza-Elizondo MA (2015) Factors associated with treatment of osteoarthritis: analysis of a COPCORD study in Nuevo Leon, Mexico. Reumatol Clin 11(4):204–209CrossRefPubMed
12.
Moreno-Montoya J, Álvarez-Nemégyei J, Trejo-Valdívia B, Peláez-Ballestas I (2014) Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument. Clin Rheumatol 33(5):631–636CrossRefPubMed
13.
Burgos-Vargas R, Cardiel MH, Loyola-Sánchez A et al (2014) Characterization of knee osteoarthritis in Latin America. A comparative analysis of clinical and health care utilization in Argentina, Brazil, and Mexico. Reumatol Clin 10(3):152–159CrossRefPubMed
14.
Álvarez-Nemégyei J, Peláez-Ballestas I, Rodríguez-Amado J et al (2011) Prevalence of rheumatic regional pain syndromes in adults from Mexico: a community survey using COPCORD for screening and syndrome-specific diagnostic criteria. J Rheumatol Suppl 86:15–20
15.
Álvarez-Nemégyei J, Peláez-Ballestas I, Sanin LH, Cardiel MH, Ramírez-Angulo A, Goycochea-Robles MV (2011) Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. J Rheumatol Suppl 86:21–25
16.
Cardiel MH, Rojas-Serrano J (2002) Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 20(5):617–624PubMed
17.
Bennett K, Cardiel MH, Ferraz MB, Riedemann P, Goldsmith CH, Tugwell P (1997) Community screening for rheumatic disorder: cross cultural adaptation and screening characteristics of the COPCORD core questionnaire in Brazil, Chile, and Mexico. The PANLAR-COPCORD Working Group. Pan American League of Associations for Rheumatology. Community Oriented Programme for the Control of Rheumatic Disease. J Rheumatol 24(1):160–168PubMed
18.
Courage UU, Stephen DP, Lucius IC et al (2017) Prevalence of musculoskeletal diseases in a semi-urban Nigerian community: results of a cross-sectional survey using COPCORD methodology. Clin Rheumatol 36(11):2509–2516CrossRefPubMed
19.
Peláez-Ballestas I, Sanin LH, Moreno-Montoya J et al (2011) Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol 86:3
20.
Peláez-Ballestas I, Álvarez-Nemégyei J, Loyola-Sánchez A, Escudero ML (2016) Prevalence and factors associated with musculoskeletal disorders and rheumatic diseases in indigenous Maya-Yucateco people: a cross-sectional community-based study. Clin Rheumatol 35(1):15–23CrossRefPubMed
21.
22.
23.
24.
Reveille JD, Muñoz R, Soriano E et al (2016) Review of current workforce for rheumatology in the countries of the Americas 2012–2015. J Clin Rheumatol 22(8):405–410CrossRefPubMed
25.
Al Maini M, Adelowo F, Al Saleh J et al (2015) The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases. Clin Rheumatol 34(5):819–829CrossRefPubMed
26.
Saavedra-Salinas MA, Barrera-Cruz A, Cabral-Castañeda AR et al (2015) Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part I. Reumatol Clin 115:295–304CrossRef
27.
Saavedra-Salinas MA, Barrera-Cruz A, Cabral-Castañeda AR et al (2015) Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. Reumatol Clin 11(5):305–315CrossRefPubMed
28.
Bori-Segura G, Hernández-Cruz B, Gobbo M et al (2009) Appropriate use of non-steroidal anti-inflammatory drugs in rheumatology: guidelines from the Spanish Society of Rheumatology and the Mexican College of Rheumatology. Reumatol Clin 5(1):3–12CrossRefPubMed
29.
Comité Mexicano del Consenso de Biológicos (2006) Guías y recomendaciones del Colegio Mexicano de Reumatología para el uso de agentes biológicos en enfermos reumáticos. Reumatol Clin 2(2):78–89CrossRef
30.
31.
32.
Monográfico osteoartritis (2007) Reumatol Clin Supl 3(SE3):1–69
33.
Monográfico Miopatías inflamatórias (2009) Reumatol Clin Supl 5(S3):1–40
34.
Monográfico vasculitis (2011) Reumatol Clin Supl 7(S3):1–46
35.
Anatomía Clínica Musculoesquelética (2012) Reumatol Clin Supl 8(S2):1–52
36.
García-Méndez S, Arreguín-Reyes R, López-López O, Vázquez-Mellado J (2014) Frequency of gout according to the perception of physicians in Mexico. Reumatol Clin 10(3):197–198CrossRefPubMed
37.
38.
39.
García R, Araujo DV (2016) The regulation of biosimilars in Latin America. Curr Rheumatol Rep 18(3):16CrossRefPubMed
40.
Espinosa-Morales R, Díaz-Borjón A, Barile-Fabris LA et al (2013) Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin 9(2):113–116CrossRefPubMed
41.
Xibille D, Carrillo S, Huerta-Sil G et al (2018) Escenario actual de los medicamentos biocomparables en México: posicionamiento del Colegio Mexicano de Reumatología, 2016. Reumatol Clin 14(3):127–136CrossRefPubMed
42.
Descalzo M, Carmona L (2010) Biobadaser 2.0: analysis and trends in 2009. Reumatol Clin (English Edition) 6(5):240–243CrossRef
43.
44.
45.
46.
47.
Pineda C, Caballero-Uribe CV, de Oliveira MG et al (2015) Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol 34(4):635–640CrossRefPubMedPubMedCentral
48.
49.
Galarza-Delgado DA, Azpíri-López JR, Colunga-Pedraza IJ et al (2017) Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis. Rheumatol Int 37(9):1507–1511CrossRefPubMed
50.
Bautista-Molano W, Landewe R, Burgos-Vargas R et al (2018) Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study. J Rheumatol 45(2):206–212CrossRefPubMed
51.
Muñoz-Louis R, Medrano-Sánchez J, Montufar R (2015) Rheumatoid arthritis in Latin America: challenges and solutions to improve its diagnosis and treatment training for medical professionals. Clin Rheumatol 34(Suppl 1):S67–S70CrossRefPubMed
52.
Saavedra MA, Villaseñor-Óvies P, Harfush LA et al (2016) Educational impact of a clinical anatomy workshop on 1st-year orthopedic and rheumatology fellows in Mexico city. Clin Rheumatol 35(5):1299–1306CrossRefPubMed
53.
Pineda C, Filippucci E, Chávez-López M et al (2008) Ultrasound in rheumatology. The Mexican experience. Clin Exp Rheumatol 26(5):929–932PubMed
54.
Chávez-López M, Pineda C (2012) Musculoskeletal ultrasound in Mexico 10 years after its inception. Reumatol Clin 8(6):304–305CrossRefPubMed
55.
Pineda C, Reginato AM, Flores V et al (2010) Pan-American League of Associations for Rheumatology (PANLAR) recommendations and guidelines for musculoskeletal ultrasound training in the Americas for rheumatologists. J Clin Rheumatol 16(3):113–118CrossRefPubMed
56.
Pineda C, Sandoval H (2017) Impactos probables de la reforma migratoria estadounidense: algunos escenarios para la reumatología mexicana. Reumatol Clin 13(4):185–188CrossRefPubMed
57.
58.
59.
60.
Treviño CV, Cruzalta AA (1997) Las enfermedades reumáticas entre los nahuas prehispánicos. Estud Cult Náhuatl 27:528
61.
Muriel J (1990) Hospitales de la Nueva España: Fundaciones del siglo XVI. Universidad Nacional Autónoma de México, Mexico
62.
De la Cruz M (1991) Libellus de Medicinalibus Indorum Herbis: Manuscrito azteca de 1552 según traducción latina de Juan Badiano. Instituto Mexicano del Seguro Social, Mexico
63.
64.
López de Hinojosos AS (1977) Recopilación de cirurgía, con un arte para sangrar muy útil y provechosa. Antonio Ricardo, México, 1578. Edición de la Academia Nacional de Medicina, México
65.
Águila Y (1988) “El periodismo científico en Nueva España: Alzáte y Bartolache (1768–1773)”. La América española en la época de las luces. Ediciones de Cultura Hispánica, Madrid
66.
Tedeschi S (2010) “Una literatura entre dilaciones, incertidumbres y ansia de modernidad”. Historia de la cultura literaria en Hispanoamérica I. FCE, México
67.
Aceves-Ávila FJ, Fraga A (1997) Las enfermedades reumáticas en el México colonial. Gac Med Mex 133(4):243–250
68.
Neri Vela R, Liévano-Madrigal L (2017) Páginas en la historia de la reumatología en México. Rev Fac Med UNAM 60(1):30–37
69.
Arce Salinas A, Pascual Ramos V (2015) La certificación del reumatólogo, experiencia en México. Acta Reumatol 2(1):1–4
70.
Martínez-Lavín M (2014) Aportaciones de la Reumatología Mexicana al Conocimiento Médico. In: Ruelas Barajas E, Lifshitz Guinzberg A (eds) Estado del Arte de la Medicina 2013–2014: Medicina. Academia Nacional de Medicina, Ciudad de México, pp 29–38
71.
Metadata
Title
Mexican rheumatology: where do we stand?
Authors
Carlos Pineda
Hugo Sandoval
Antonio Fraga-Mouret
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 4/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4198-7

Other articles of this Issue 4/2019

Rheumatology International 4/2019 Go to the issue

Public Health

Disability due to rheumatic diseases in the city of Junín, Argentina

Systematic review

Real-world incidence and prevalence of low back pain using routinely collected data

Systematic review

Fatty infiltration in the thigh muscles in knee osteoarthritis: a systematic review and meta-analysis

Observational Research

Hand grip endurance moderating the effect of grip force on functional ability and disease activity in rheumatoid arthritis patients: a cross-sectional study

Case Based Review

Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review

Public Health

Accuracy, completeness and accessibility of online information on fibromyalgia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits